Actinomycin D is a classic antibiotic used in research and cancer therapy that blocks RNA synthesis by binding DNA. This MCQ targets its precise mechanism, crucial for understanding gene expression regulation in eukaryotes versus prokaryotes.

Correct Answer: 1. Transcriptional elongation in Eukaryotes

Actinomycin D intercalates into DNA at GC-rich regions, preventing RNA polymerase II from elongating the transcript after initiation. In eukaryotes, it stabilizes in the transcription complex, halting chain progression without affecting initiation directly. This makes it a key tool for studying mRNA stability, as ongoing transcription stops rapidly.

Why Not the Other Options?

Here’s why each alternative fails, clarifying common confusions in prokaryotic versus eukaryotic systems:

• 2. Translational elongation in prokaryotes
  Translation involves ribosomes on mRNA, not DNA binding. Actinomycin D targets transcription, not protein synthesis elongation in prokaryotes or anywhere; antibiotics like cycloheximide handle eukaryotic translation.

• 3. Transcriptional initiation in prokaryotes
  Prokaryotic initiation uses sigma factors on promoters. Actinomycin D allows initial RNA polymerase binding but blocks elongation in both domains; rifampicin specifically inhibits prokaryotic initiation.

• 4. Translational initiation in eukaryotes
  Eukaryotic translation initiation recruits eIFs and the 40S subunit. Actinomycin D acts upstream at transcription, not on ribosomes or mRNA cap scanning; its effects on translation are indirect via mRNA depletion.

Mechanism Highlights

Actinomycin D’s phenoxazone ring slips between DNA base pairs, distorting the helix and jamming RNA polymerase movement. Eukaryotes rely heavily on this drug in lab settings for half-life assays, as it spares short transcripts initially. In oncology, it triggers apoptosis by silencing anti-apoptotic genes. For biology students, note its broader eukaryotic sensitivity over prokaryotes due to polymerase differences.